EANS-News: november Aktiengesellschaft
Annual Shareholders´ Meeting May 17,
2011 in Cologne
november AG plans a significant capital reduction to cover losses
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. --------------------------------------------------------------------------------
Annual & Special Corporate Meetings
Subtitle: november AG plans a significant capital reduction to cover losses
Köln (euro adhoc) - The november AG (WKN A0Z24E), listed in the Prime Standard of the German Stock Exchange (Deutsche Börse) is holding its General Meeting on May 17, 2011 at the Mediapark, Cologne.
Most important item of the agenda is the resolution on a capital reduction of the nominal capital in simplified form by combining of shares for the purpose of covering losses.
To cover losses, november AG plans to reduce the share capital by a simplified capital decrease in the ratio 5:1 from presently EUR 5.142.462,--, divided into 5.142.462 bearer shares, to EUR 1.028.492,--, divided into 1.028.492 bearer shares, according to the regulations of a debt-equity-swap (§§ 229 ff AktG).
This capital reduction shall cover accumulated losses of previous years. The measures complete the restructuring activities of the last few years and shall make november AG suitable again for capital markets.
By focusing on the core business, the certification and significantly increased sales and earning rates of PROGEN Biotechnik GmbH, november AG for the first time in its history has a profitable core business with PROGEN Biotechnik GmbH and the objective is to develop and expand this business.
For further information on the upcoming General Meeting on May 17, 2011 please refer to: hv.november.de
end of announcement euro adhoc --------------------------------------------------------------------------------
Contact:
Dr. Dirk Zurek
Vorstand
Tel.: +49 (0) 221 82200 520 10
E-Mail: ir@november.de
Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade